News Releases

Date Title
11/12/19
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting  Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial
11/08/19
Summary ToggleSunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 28 th Annual Credit Suisse Healthcare
11/06/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61 st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida .
10/29/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on November 12th to Discuss Third Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, November 12 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/16/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massachusetts
09/19/19
Summary ToggleSunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto , M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development experience to the Board. “Dr.
08/28/19
Summary ToggleSunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President of Finance and Corporate Development, will present at the Wells Fargo Healthcare Conference on
08/07/19
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2019 . Loss from operations for the three and six months ended
07/31/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, August 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended
07/11/19
Summary ToggleSunesis Announces Pricing of $25 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock
07/10/19
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , July 10, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series F Convertible Preferred Stock in underwritten public
07/08/19
Summary ToggleSunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update 300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling SOUTH SAN FRANCISCO, Calif. , July 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox , Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific
06/15/19
Summary ToggleSunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting SOUTH SAN FRANCISCO, Calif. , June 15, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic
05/08/19
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March
05/01/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Wednesday, May 8 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended
04/29/19
Summary ToggleSunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank SOUTH SAN FRANCISCO, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank . The new agreement allows the company to retire its existing loan and defer any principal
04/03/19
Summary ToggleSunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18 th Annual
03/07/19
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2018 .
03/04/19
Summary ToggleSunesis Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor conferences in March: Event: Cowen and Company 39 th Annual Health Care Conference Date: Monday, March 11 th
02/28/19
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, March 7 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and
01/17/19
Summary ToggleSunesis Announces Pricing of $20 Million Offering of Securities SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock
01/17/19
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock and Preferred Stock SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public
01/02/19
Summary ToggleSunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies - 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent